Session Information
Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity
Session Type: Abstract Submissions (ACR)
Distribution and clinical significance of anti-heterogeneous nuclear ribonucleoprotein A2 antibody in connective tissue diseases
Abstract:
Background/Purpose:
The heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) has been described as an important autoantigen in rheumatoid arthritis (RA) since it is targeted by autoantibodies. To explore clinical significance of anti-heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2) antibody, we dectect the distribution of anti-hnRNP-A2 antibody in 1888 patients with connective tissue diseases.
Methods:
Serum anti-hnRNP A2 antibody level was measured by solid-phase enzyme linked immunosorbent assay (ELISA) in 1464 patients with RA, 209 patients with systemic lupus erythematosus (SLE), 63 patients with mixed connective tissue disease (MCTD) , 60 patients with Sjogren syndrome (SS), 47 patients with polymyositis/dermatomyositis (PM/DM), and 45 patients with systemic sclerosis (SSc). The positivity rate of anti-hnRNP-A2 antibody was compared among various patient groups, and its correlation to clinical and laboratory parameters and its diagnostic significance were analyzed.
Results:
The positivity rate of anti-hnRNP-A2 antibody was 38.0%(556/1464), 36.8%(77/209), 52.4%(33/63), 5.0%(3/60), 4.3%(2/47), and 8.9%(4/45) in RA, SLE, MCTD, SS, PM/DM and SSc, respectively. The rate differed insignificantly between the RA, SLE and MCTD groups (P>0.05), but was significantly higher than in other disease groups (P<0.01). The titers of anti-hnRNP-A2 antibody were significantly higher in the RA, SLE, MCTD groups than in other disease groups (P<0.01), but differed insignificantly between the RA, SLE, MCTD groups (P>0.05). In RA patients, anti-hnRNP-A2 antibody weakly correlated negatively to anti-Cyclic citrullinated peptide (CCP) antibody (r=-0.135, P<0.01), but correlated insignificantly to age, course of disease, time of morning stiffness, erythrocyte sedimentation rate, C reactive protein, rheumatoid factor (RF), anti-keratin antibody (AKA) and glucose phosphate isomerase (GPI) (P>0.05).
Conclusion:
Anti-hnRNP-A2 antibody can be found in various connective tissue diseases, and its positivity rate is relatively high in RA, SLE and MCTD. It is not a RA-specific antibody. In RA, anti-hnRNP-A2 antibody does not coincide with other RA-related serological indicators; hence, it may serve as an adjunctive indicator for RA diagnosis.
Key Words: heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2); Rheumatoid Arthritis (RA); Connective Tissue Diseases
Disclosure:
W. Yong Sr.,
None;
M. Fangxiang,
None;
W. Hong,
None;
F. Yongfei,
None.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/distribution-and-clinical-significance-of-anti-heterogenic-nuclear-ribonucleoprotein-a2-antibody-in-connective-tissue-diseases/